CoThera Secures Key Grant to Accelerate Post-Operative Recovery Innovation with VPULSE™ Technology

CoThera, a division of United Orthopedic Group and an industry leader in manufacturing and distributing innovative medical products, today announced a new funding milestone that will drive its mission of improving and promoting the recovery phase of post-operative treatment. In its latest round of strategic investment, CoThera raised $0, a move that underscores the company's commitment to refining its cutting-edge solutions rather than focusing solely on capital metrics. This round of funding is dedicated to advancing the development of its revolutionary, patent-pending VPULSE™ technology—a unique therapeutic system that combines multiple rehabilitative therapies in one seamless application. Designed primarily for patients recovering from orthopedic surgery, VPULSE™ provides an integrated approach to treat acute post-operative pain and significantly mitigate serious complications such as deep vein thrombosis (DVT) and pulmonary embolism. Recognizing that the recovery period is as critical to a patient’s healing journey as the surgical procedure itself, CoThera continuously seeks to innovate and streamline post-surgical care. The current infusion will enable the company to further enhance its product development efforts, expand research initiatives, and solidify its market presence as a trusted provider of recovery-focused treatments. While the monetary figure may not immediately capture headlines, the strategic value of the investment lies in its potential to accelerate life-changing innovations and set new benchmarks in patient care. By combining therapies for enhanced recovery, CoThera remains steadfast in its vision to not only support surgeons and healthcare providers but also to empower patients with safer, more effective solutions for a smoother recovery.